Methylation & B-Complex

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Methylation & B-Complex - References

---

1. Pharmacodynamics & Mechanism of Action

The One-Carbon Metabolism & Methylation Cycle links the folate cycle, the methionine cycle, and the transsulfuration pathway to produce S-Adenosylmethionine (SAMe)—the universal methyl donor for $>200$ methyltransferases governing DNA/histone epigenetics (DNMTs), phosphatidylcholine synthesis (PEMT), neurotransmitter synthesis/catabolism (COMT, PNMT), and Creatine & Phosphocreatine System synthesis (GAMT).

• Folate & Methionine Remethylation: Dietary folate is reduced via DHFR and converted by MTHFR (a flavoprotein requiring FAD / Vitamin B2) into 5-methyltetrahydrofolate (5-MTHF). Methionine Synthase (MTR), using Methylcobalamin (B12) as a prosthetic group and MTRR (requiring FAD/FMN) for reactivation, transfers the methyl group from 5-MTHF to homocysteine, regenerating methionine.
• Hepatic/Renal Shunt (BHMT): Trimethylglycine (TMG / Betaine), derived from Cholinergics (Alpha-GPC, Citicoline) oxidation, donates a methyl group directly to homocysteine via Betaine-Homocysteine S-Methyltransferase (BHMT) independent of folate and B12.
• Transsulfuration Pathway: Pyridoxal-5’-Phosphate (P5P / Active B6) serves as the obligate cofactor for Cystathionine $\beta$-Synthase (CBS) and Cystathionine $\gamma$-Lyase (CTH), irreversibly converting excess homocysteine into cysteine, taurine, and glutathione (GSH).

---

2. Pharmacokinetics & Genetic Polymorphism Matching

• 5-MTHF vs. Synthetic Folic Acid: Synthetic folic acid requires two slow reductions via hepatic DHFR; intakes $>200\text{–}400\mu \text{g}$ saturate DHFR, leading to circulating Unmetabolized Folic Acid (UMFA) which competitively blocks folate receptors (FR-$\alpha$) at the choroid plexus. L-5-MTHF (glucosamine or calcium salt) bypasses DHFR and MTHFR polymorphisms (C677T and A1298C, which reduce MTHFR enzymatic activity by $35\text{–}70\%$).
• Cobalamin Isoforms:
  • Methylcobalamin: Cytosolic methyl donor for MTR.
  • Adenosylcobalamin: Mitochondrial cofactor for Methylmalonyl-CoA Mutase (MMUT) in odd-chain fatty acid and branched-chain amino acid catabolism.
  • Hydroxocobalamin: Nitric oxide scavenger and depot precursor preferred in individuals with slow COMT (Val158Met Met/Met) who experience restlessness or anxiety (“overmethylation”) from exogenous methyl donors.
• Pyridoxal-5’-Phosphate (P5P) vs. Pyridoxine HCl: High-dose inactive pyridoxine HCl ($>50\text{–}100\text{ mg/day}$) competitively inhibits endogenous P5P-dependent enzymes, inducing paradoxical sensory neuropathy (“Vitamin B6 paradox”). P5P avoids hepatic pyridoxine kinase bottlenecking at physiological doses ($10\text{–}25\text{ mg}$).

---

3. Dosing, Cycling & Synergies

• Standard Protocol:
  • Riboflavin-5’-Phosphate (B2): $10\text{–}25\text{ mg/day}$ (up to $100\text{–}400\text{ mg}$ in homozygous MTHFR C677T TT to stabilize FAD binding).
  • L-5-MTHF (B9): $400\text{–}800\mu \text{g/day}$.
  • Cobalamin (B12): $500\text{–}1,000\mu \text{g/day}$ sublingual (Methylcobalamin + Adenosylcobalamin, or Hydroxocobalamin).
  • Pyridoxal-5’-Phosphate (B6): $10\text{–}25\text{ mg/day}$.
  • TMG (Betaine): $1,000\text{–}2,500\text{ mg/day}$.
• Synergies: Creatine & Phosphocreatine System (consumes $\sim 40\%$ of endogenous SAMe via GAMT; exogenous creatine spares methyl groups) and Amino Acids & Precursors (Glycine acts as the “methyl buffer” via GNMT, converting excess SAMe into sarcosine).
• Contraindications & Biomarkers to Monitor:
  • Contraindications/Precautions: Avoid high-dose methylated B-vitamins in acute mania or unbuffered slow-COMT phenotypes without glycine/niacinamide support. Never administer high-dose folate without verifying B12 status (risk of masking megaloblastic anemia while subacute combined degeneration progresses).
  • Biomarkers: Plasma Fasting Homocysteine (optimal: $5.5\text{–}7.5\mu \text{mol/L}$), Holo-Transcobalamin (Active B12), Serum/Urinary Methylmalonic Acid (MMA), RBC Folate, and SAMe:SAH ratio.

---

4. Key Scientific Evidence Summary

• VITACOG Brain Atrophy Trial: Smith et al. (2010) and Douaud et al. (2013) demonstrated in PLoS ONE and PNAS that homocysteine-lowering B-vitamins slowed total brain atrophy by $-29.6\%$ (and up to $-53\%$ in subjects with baseline homocysteine $>13\mu \text{mol/L}$) and reduced Alzheimer’s-vulnerable gray matter atrophy by 7-fold.
• Riboflavin & MTHFR C677T: McNulty et al. (2006) and Horigan et al. (2010) proved that $1.6\text{ mg/day}$ riboflavin restores MTHFR enzyme stability in MTHFR 677TT homozygotes, lowering homocysteine by $-22\%$ and systolic blood pressure by $-9.2\text{ to }-13\text{ mmHg}$.

See full study breakdowns in Methylation & B-Complex - References.